PMCBMEDIUM SIGNALFINANCIAL10-K

PMCB substantially reduced its share buyback activity while significantly strengthening its balance sheet through debt reduction and equity growth.

The company appears to be shifting from capital return activities to debt reduction and operational focus, as evidenced by the dramatic decline in share buybacks from $28.2M to $2.5M. The substantial improvement in stockholders' equity coupled with meaningful debt reduction suggests improved financial stability, though the company continues to burn cash operationally.

Comparing 2025-08-11 vs 2024-08-13View on EDGAR →
FINANCIAL ANALYSIS

PMCB's balance sheet strengthened considerably with stockholders' equity growing to $51.9M while total liabilities declined sharply to $3.3M, indicating significant deleveraging. However, the company's cash position fell notably to $15.2M and operating cash flow remained negative at -$3.0M, reflecting ongoing operational cash burn. The dramatic reduction in share buybacks suggests management is prioritizing cash preservation and debt reduction over returning capital to shareholders.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-91%
$28.2M$2.5M

Buyback activity reduced 91% — capital being redeployed elsewhere or cash conservation underway.

Stockholders Equity
Balance Sheet
+87.7%
$27.6M$51.9M

Equity base grew 87.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Liabilities
Balance Sheet
-83.9%
$20.4M$3.3M

Liabilities reduced 83.9% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-69.8%
$50.2M$15.2M

Cash declined 69.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
-60.7%
$7.4M$2.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-55.6%
$50.4M$22.4M

Current assets declined 55.6% — monitor working capital adequacy and short-term liquidity.

Operating Income
P&L
+48.6%
-$8.5M-$4.4M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
-38.4%
-$2.2M-$3.0M

Operating cash flow fell 38.4% — earnings quality concerns; investigate working capital changes and non-cash items.

Accounts Receivable
Balance Sheet
+11.4%
$2K$3K

Receivables grew 11.4% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2025-08-11
PRIOR — 2024-08-13
ADDED
As of August 4, 2025, the registrant had 6,795,779 outstanding shares of common stock.
In addition to reengaging SG Austria, we are also identifying alternative approaches to expand the prodrug/activator technology for cancer treatment.
This is a scalable technology that permits real-time analysis of long DNA fragments.
During the year ended April 30, 2025, our scientific consultants have been in active dialog with the FDA seeking permission to forego the large animal study.
The technology upon which the LAPC treatment will be based, intra-arterial chemotherapy, has been used in five clinical trials in humans.
+7 more — sign up free →
REMOVED
As of August 8, 2024, the registrant had 7,709,459 outstanding shares of common stock.
On August 15, 2022, we entered into a Cooperation Agreement (the Cooperation Agreement ) with Iroquois Master Fund Ltd.
and its affiliates, pursuant to which we elected a reconstituted board of directors (the Board ).
In addition to reengaging SG Austria, the Company is also identifying alternative approaches to expand the prodrug/activator technology for cancer treatment.
This is a cutting edge, unique and scalable technology that permits real-time analysis of long DNA fragments.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →